Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono- and bis-3-O-sulphamates

International Journal of Cancer

Volumn 117, Issue 1, 2005, Pages 150-159

  Raobaikady, Bindumalini ^a   Reed, Michael J ^a   Leese, Mathew P ^b   Potter, Barry V L ^b   Purohit, Atul ^a  

^a ST MARY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BATH   (United Kingdom)

Author keywords

Antiproliferative effects; Breast cancer; Methoxyoestrogens; Microtubules; Oestrogen sulphamates

Indexed keywords

2 ETHYLESTRADIOL 3 O SULFAMATE; 2 ETHYLESTRADIOL 3,17 O,O BISSULFAMATE; 2 ETHYLESTRADIOL BIS 3 O SULFAMATE; 2 METHOXYESTRADIOL; 2 METHOXYESTRONE 3 O SULFAMATE; 2 METHOXYESTRONE BIS 3 O SULFAMATE; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR ALPHA; MATRIGEL; PROTEIN BCL 2; SULFUR DERIVATIVE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CELL CULTURE; CELL CYCLE G2 PHASE; CELL NUCLEUS INCLUSION BODY; CELL PROLIFERATION; CHEMICAL REACTION; CLONOGENESIS; CONTROLLED STUDY; CYTOSKELETON; DRUG BIOAVAILABILITY; DRUG EXPOSURE; DRUG POTENCY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MICROTUBULE; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STRUCTURE ACTIVITY RELATION; SULFAMOYLATION;

BREAST NEOPLASMS; CELL DIVISION; CELL PROLIFERATION; COLLAGEN; DRUG COMBINATIONS; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; G2 PHASE; HUMANS; LAMININ; PHOSPHORYLATION; PROTEOGLYCANS; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONIC ACIDS; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY;

EID: 24344456018     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.21066     Document Type: Article

References (49)

1. Zhu BT, Conney AH. Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? Cancer Res 1998; 58:2269-77.
2. Fotsis T, Zhang Y, Pepper MS, Adlercreutz H, Montesano R, Nawroth PP, Schweigerer L. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angioaenesis and suppresses tumour growth. Nature 1994;368:237-9.
3. Seegers JC, Lottering ML, Grobler CJ, van Papendorp DH, Habbersett RC, Shou Y, Lehnert BE. The mammalian metabolite, 2-methoxyestradiol, affects p53 levels and apoptosis induction in transformed cells but not in normal cells. J Steroid Biochem Mol Biol 1997;62: 253-67.
4. Qadan LR, Perez-Stable CM, Anderson C, D'Ippolito G, Herron A, Howard GY, Roos BA. 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun 2001;285:1259-66.
5. Kumar AP, Garcia GE, Slaga TJ. 2-Methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog 2001;31:111-24.
6. Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene 1997;14:379-84.
7. Ghosh R, Ott AM, Seetharam D, Slaga TJ, Kumar AP. Cell cycle block and apoptosis induction in human melanoma cell line following treatment with 2-methoxyestradiol: therapeutic implications? Melanoma Res 2003;13:119-27.
8. Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ. Inhibition of angiogenesis and breast cancer in mice by the microlubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-6.
9. Lin HL, Liu TY, Wu CW, Chi CW. 2-Methoxyestradiol-induced caspase-3 activation and apoptosis occurs through G(2)/M arrest dependent and independent pathways in gastric carcinoma cells. Cancer 2001;92:500-9.
10. Yue TL, Wang X, Louden CS, Gupta S, Pillarisetti K, Gu JL, Hart TK, Lysko PG, Feuerstein GZ. 2-Methoxyestradiol, an endogenous estrogen metabolite, induces apoptosis in endothelial cells and inhibits angiogenesis: possible role for stress-activated protein kinase signaling pathway and Fas expression. Mol Pharmacol 1997; 51:951-62.
11. Huober JB, Nakamura S, Meyn R, Roth JA, Mukhopadhyay T. Oral administration of an estrogen metabolite-induced potentiation of radiation antitumor effects in presence of wild type p53 in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000;48: 1127-37.
12. Miller KD, Haney LG, Pribluda VS, Sledge GW. A phase I safety, pharmacokinetic and pharmacodynamic study of 2-methoxyestradiol (2ME2) in patients (Pts) with refractory metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2001; abstract 170.
13. Wilding G, Sweeney C, King DM, Horvath D, Staab MJ, Fife K, Armstrong V, Pribluda V, Gubish ER, Sidor C. Phase 2, multicenter, randomized, double blind, safety, pharmacokinetic, pharmacodynamic and efficacy study of two doses of 2-methoxyestradiol administered orally in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002; abstract 338.
14. Miller KD, Murry DJ, Curry E, Haney LG, McClaskey N, Storniolo AM, Phillips E, Pribluda VS, Gubish ER, Sledge GW. A phase I study of 2-methoxyestradiol (2ME2) plus decetaxel in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2002; abstract 442.
15. Hamel E, Lin CM, Flynn E, D'Amato RJ. Interactions of 2-methoxyestradiol, an endogenous mammalian metabolite, with unpolymerised tubulin and with tubulin polymer. Biochemistry 1996;35: 1304-10.
16. Attalla H, Westberg JA, Andersson LC, Adlercreutz H, Makela TP. 2-Methoxyestradiol-induced phosphorylation of Bcl-2: uncoupling from JNK/SAPK activation. Biochem Biophys Res Commun 1998; 247:616-9.
17. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000;407:390-5.
18. Qanungo S, Basu A, Das M, Haldar S. 2-Methoxyestradiol induces mitochondria dependent apoptotic signaling in pancreatic cancer cells. Oncogene 2002;21:4149-57.
19. D'Amato RJ, Lin CM, Flynn E, Folkman J, Hamel E. 2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. Proc Natl Acad Sci USA 1994;91:3964-8.
20. Cushman M, He HM, Kalzenellenbogen JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 1995;38:2041-9.
21. Mabjeesh NJ, Escuin D, La Vallee TM, Pribluda VS, Swartz GM, Johnson MS, Willard MT, Zhong H, Simons JW, Giannakakou P. 2ME2 inhibits tumour growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 2003;3:363-75.
22. Brueggemeier RW, Bhat AS, Lovely CJ, Couahenour HD, Joomprabutra S, Weitzel DH, Vandre DD, Yusuf F, Burak Jr WE. 2-Methoxymethylestradiol: a new 2-methoxy estrogen analog that exhibits anti-proliferative activity and alters tubulin dynamics. J Steroid Biochem Mol Biol 2001;78:145-56.
23. Tinley TL, Leal RM, Randall-Hlubek DA, Cessac JW, Wilkens LR, Rao PN, Mooberry SL. Novel 2-methoxystradiol analogues with anti-tumour activity. Cancer Res 2003;63:1538-49.
24. Purohit A, Hejaz HAM, Walden L, MacCarthy-Morrogh L, Packham G, Potter BVL, Reed MJ. The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours. Int J Cancer 2000;85:584-9.
25. MacCarthy-Morrogh L, Townsend PA, Purohit A, Hejaz HAM, Potter BVL, Reed MJ, Packham G. Differential effects of estrone and estrone-3-O-sulfamate derivatives on mitotic. Arrest, apoptosis, and microtubule assembly in human breast cancer cells. Cancer Res 2000;60:5441-50.
26. Suzuki RN, Newman SP, Purohit A, Leese MP, Potter BVL, Reed MJ. Growth inhibition of multi-drug-resistant breasl cancer cells by 2-methoxyoestradiol- bis-sulphamate and 2-ethyloestradiol-bis-sulphamate. J Steroid Biochem Mol Biol 2003;84:269-78.
27. Day JM, Newman SP, Comninos A, Solomon C, Purohit A, Leese MP, Potter BVL, Reed MJ. The effects of 2-substituted oestrogen sulphamates on growth of prostate and ovarian cancer cells. J Steroid Biochem Mol Biol 2003;84:317-25.
28. Newman SP, Leese MP, Purohit A, James DRC, Rennie CR, Potter BVL, Reed MJ. Inhibition of in vitro angiogenesis by 2-methoxy- and 2-ethyl-estrogen sulphamates. Int J Cancer 2004;109:533-40.
29. Okada M, Iwashita N, Koizumi N. Efficient general method of sulphamoylation of a hydroxyl group. Tetrahydron Lett 2000;41:7047-51.
30. Leese MP, Hejaz HAM, Mahon MF, Newman SP, Purohit A, Reed MJ, Potter BVL. A ring substituted estrogen-3-O-sulfamates: potent multi-targeted anticancer agents. J Med Chem (in press).
31. Sorger PK, Dobles M, Tournebize R, Hyman AA. Coupling cell division and cell death to microtubule dynamics. Curr Opin Cell Biol 1997;9:807-14.
32. Jordan MA, Wilson L. Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10:123-30.
33. Woods CM, Zhu J, McQueney PA, Lazarides E. Taxol-induced mitotic block triggers rapid onset of p53-independent apoptotic pathway. Mol Med 1995;1:506-26.
34. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25.
35. Reider CL, Palazzo RE. Colcemid and mitotic cycle. J Cell Sci 1992;102:387-92.
36. Pribluda VS, Gubish Jr ER, LaVallee TM, Treston A, Swartz GM, Green SJ. 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metast Rev 2000;19:173-9.
37. Attalla H, Makela TP, Adlercreutz H, Andersson LC. 2-Methoxyestradiol arrests cells in mitosis without depolymerising tubulin. Biochem Biophys Res Commun 1996;228:467-73.
38. Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res 1998;58:1609-15.
39. Basu A, Haldar S. Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl2 protein. Int J Oncol 1998;13:659-64.
40. Wood L, Leese MP, Mouzakiti A, Purohit A, Potter BVL, Reed MJ, Packham G. 2-MeOE2bisMATE induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases. Apoptosis 2004;9:323-32.
41. Ireson CR, Chander SK, Purohit A, Perera S, Newman SP, Parish D, Leese MP, Smith AC, Potter BVL, Reed MJ. Pharmacokinetics and efficacy of 2-methoxyoestradiol and 2-methoxyoestradiol-bis-sulphamate in vivo in rodents. Br J Cancer 2004;90:932-7.
42. Chander SK, Ireson CR, Fenton J, Newman SP, Leese MP, Poter BVL, Purohit A, Reed MJ. Comparision of 2-methoxyoestradiol and 2-methoxyoestradiol-3, 17-bis-sulphamate in the Matrigel plug angiogenesis mouse model. Proc Am Assoc Cancer Res 2003: abstract R1156.
43. Reed MJ, Purohit A, Woo LWL, Potter BVL. The development of steroid sulphatase inhibitors. Endocrin Rel Cancer 1996;3:9-23.
44. Woo LWL, Howarth NM, Purohit A, Hejaz HAM, Reed MJ, Potter BVL. Steroidal and nonsteroidal sulfamates as potent inhibitors of steroid sulfatase. J Med Chem 1998;41:1068-83.
45. Purohit A, Woo LWL, Barrow D, Hejaz HAM, Nicholson RI, Potter BVL, Reed MJ. Non-steroidal and steroidal sulfamates: new drugs for cancer therapy. Mol Cell Endocrinol 2001;171:129-35.
46. Purohit A, Vernon KA, Hummelinck AE, Woo LWL, Hejaz HAM, Potter BVL, Reed MJ. The development of A-ring modified analogues of oestrone-3-O-sulphamate as potent steroid sulphatase inhibitors with reduced oestrogenicity. J Steroid Biochem Mol Biol 1998;64: 269-75.
47. Raobaikady B, Purohit A, Chander SK, Woo LWL, Leese MP, Potter BVL, Reed MJ. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase inhibition by 2-methoxyoestradiol-bis-sulphamate. J Steroid Biochem Mol Biol 2003;84:351-8.
48. Lee AJ, Liu ZJ, Zhu BT. Lack of biological activity of 2-methoxyestradiol-3-sulfate and its differential metabolic formation in human breast cancer. Proc Am Assoc Cancer Res 2002; abstract 5398.
49. Sledge GW, Miller KD, Haney LG, Nguyen DD, Storniolo AM, Phillips EN, Pribluda V. A phase I study of 2-methoxyestradiol (2ME2) in patients (Pts) with refractory metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2002; abstract 441.